Skip to main content
Clinical Trials/NCT05745805
NCT05745805
Recruiting
N/A

Cohort Follow-up of Epidemic and Neuroimaging for Patients During the 1st Wave of the COVID-19 in China

First Affiliated Hospital Xi'an Jiaotong University1 site in 1 country600 target enrollmentJanuary 12, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
COVID-19
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Enrollment
600
Locations
1
Primary Endpoint
Change in brain function.
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Our main objective is to analyze the development of physical impact, mental health and blood profile over follow-up time during the 1st wave of the COVID-19. Besides, we aim to establish a database of post-COVID-19 based on simultaneous cortico-spinal magnetic resonance imaging data to identify high-risk patients with long COVID and prevent the neurological symptoms evolution, optimize the tactics of management in China.

Detailed Description

This is an observational, cross-sectional, and multicenter study. It will be performed at 9 public hospitals. Participants with confirmed cases of mild or moderate COVID-19 infection will complete the following programs at acute infection phase and after 3, 12 months for exploring biological mechanism and predictive biomarkers of post-COVID-19: 1) fill in the behavioral psychology scales, 2) submit blood samples at a local laboratory, 3) accept the simultaneous cortico-spinal magnetic resonance imaging scan. The uninfected healthy controls will complete the same programs as infected group mentioned above only at the time of inclusion. We will establish the simultaneous cortico-spinal magnetic resonance imaging database containing neuropsychological scales and blood parameters of post-COVID-19 in China.

Registry
clinicaltrials.gov
Start Date
January 12, 2023
End Date
September 12, 2026
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Confirmed diagnosis of mild Covid-19 (WHO criteria)/Confirmed diagnosis of moderate Covid-19 (WHO criteria)/Healthy people who have not had COVID-19

Exclusion Criteria

  • History of central nervous system diseases, such as mental disorder, degenerative diseases of central nervous system, tumors, trauma, etc. Participants with indication for MRI studies

Outcomes

Primary Outcomes

Change in brain function.

Time Frame: baseline and 3, 12 months

The changes of brain functional connectivity intensity are evaluated by functional MRI

Change in brain structure.

Time Frame: baseline and 3, 12 months

The changes of brain volume (mm3) are evaluated by structural MRI

Secondary Outcomes

  • Change in pain.(baseline and 3, 12 months)
  • Change in executive function.(baseline and 3, 12 months)
  • Changes in symptoms assessed with a Symptom Checklist-90 Somatization (SCL-90 SOM) subscale.(baseline and 3, 12 months)
  • Change in Fatigue.(baseline and 3, 12 months)
  • Change in Post-Traumatic Stress Disorder.(baseline and 3, 12 months)
  • Change in cognition.(baseline and 3, 12 months)
  • Change in Inflammatory markers.(baseline and 3, 12 months)
  • Change in anxiety.(baseline and 3, 12 months)
  • Change in Sleep.(baseline and 3, 12 months)
  • Change in depression.(baseline and 3, 12 months)
  • Change in verbal memory.(baseline and 3, 12 months)
  • Change in auditory attention.(baseline and 3, 12 months)
  • Change in myocardial enzymes.(baseline and 3, 12 months)
  • Change in working memory.(baseline and 3, 12 months)
  • Change in Ig G and Ig M.(baseline and 3, 12 months)

Study Sites (1)

Loading locations...

Similar Trials